FDA expands orphan drug designation for Roswell Park's brain cancer immunotherapy

1 year ago 35

The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center.

1. Homepage
2. Brain Cancer
3. FDA expands orphan drug designation for Roswell Park's brain cancer immunotherapy